VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research report released on Wednesday morning. The brokerage issued a sell rating on the stock.

Separately, Benchmark reissued a “hold” rating on shares of VolitionRx in a research note on Friday, August 16th.

VolitionRx Stock Down 0.8 %

NYSE VNRX opened at $0.80 on Wednesday. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.23. The firm has a market capitalization of $74.54 million, a price-to-earnings ratio of -2.23 and a beta of 1.10. The company has a fifty day moving average of $0.69 and a two-hundred day moving average of $0.68.

Institutional Trading of VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Geode Capital Management LLC lifted its position in VolitionRx Limited (NYSE:VNRX) by 15.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 730,448 shares of the company’s stock after purchasing an additional 95,900 shares during the quarter. Geode Capital Management LLC owned about 0.79% of VolitionRx worth $439,000 as of its most recent SEC filing. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.